Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
A phase 3 trial of Plerixafor in Multiple myeloma, run by Genzyme, a Sanofi Company, completed.
Overview
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients is a phase 3 interventional study registered as NCT00103662 by Genzyme, a Sanofi Company, with 302 participants recorded, started 2005-01 and reaching its primary completion in 2006-10. Interventions recorded: Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo. Conditions recorded: Multiple Myeloma.
Linked to the drug Plerixafor because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialFilgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
Shares Plerixafor, Multiple myeloma and the tag pipeline.
- TrialEvaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Shares Plerixafor, Sanofi and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
Shares Sanofi and the tag pipeline.
- TrialA New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen
Shares Sanofi and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialIsatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Shares Sanofi, Multiple myeloma and the tag pipeline.
- TrialTwo Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
Shares Sanofi and the tag pipeline.